ClinicalTrials.gg
CompletedNCT05355402Updated Apr 23, 2026Results posted

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

A Phase 2 interventional study of Olezarsen and Placebo in Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease and Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Hypertriglyceridemia · Ionis Pharmaceuticals, Inc..

Enrollment
5th of 12
154 · median 114
Started
2022
with 3 others
Phase 2
5 of 12
1 open now
Registered
8th of 12
by date

Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., this one is the 5th largest by enrollment, is one of 4 that started in 2022, is one of 5 in phase 2, and was the 8th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

1 of the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG. Other objectives were to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).

Read the detailed description

This was a multi-center, randomized, double-blind, placebo-controlled study in participants with hypertriglyceridemia (triglycerides > 150 milligrams per deciliter [mg/dL]) and established or at increased risk for atherosclerotic cardiovascular disease, and/or with severe hypertriglyceridemia. The study had an up to 8-week screening period, a 53-week treatment period, and a 13-week post-treatment follow-up period.

03

Conditions studied

  • Hypertriglyceridemia
  • Atherosclerotic Cardiovascular Disease
  • Severe Hypertriglyceridemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years at the time of
  2. Fall into at least 1 of the following groups (a or b):

    1. Hypertriglyceridemia with fasting TG ≥ 150 mg/dL (1.69 millimoles per liter [mmol/L]) and \< 500 mg/dL (5.65 mmol/L) with either clinical diagnosis of atherosclerotic cardiovascular disease (ASCVD) or at increased risk for ASCVD
    2. Severe hypertriglyceridemia with fasting TG ≥ 500 mg/dL (5.65 mmol/L).
  3. Participants must be on standard-of-care (SOC), lipid-lowering medications per local guidelines.
  4. Participants must be willing to comply with diet and lifestyle recommendations as able.

Exclusion criteria

Exclusion Criteria:

  1. Diabetes with any of the following:

    1. Newly diagnosed within 12 weeks of screening
    2. (HbA1c) ≥ 9.5% at Screening
    3. Change in basal insulin regimen > 20% within 3 months prior to Screening
    4. For participants with type 1 diabetes: episode of diabetic ketoacidosis, or ≥ 3 episodes of severe hypoglycemia within 6 months prior to Screening
  2. Acute coronary syndrome or stroke/ (TIA) within 6 months prior to Screening
  3. Major surgery, peripheral revascularization, or non-urgent percutaneous coronary intervention (PCI) within 3 months prior to Screening, or upcoming planned major surgery or major procedure (e.g., arterial revascularization) during the course of the study
  4. Active pancreatitis within 4 weeks prior to Screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received olezarsen-matching placebo, as a single subcutaneous (SC) injection, once every 4 weeks for 53 weeks treatment period.

    Drug: Placebo

  • Experimental
    Olezarsen 50 mg

    Participants received olezarsen 50 mg, as a single 0.5 milliliters (mL) SC injection, once every 4 weeks for 53 weeks treatment period.

    Drug: Olezarsen

  • Experimental
    Olezarsen 80 mg

    Participants received olezarsen 80 mg, as a single 0.8 mL SC injection, once every 4 weeks for 53 weeks treatment period.

    Drug: Olezarsen

Interventions

  • SC injection.

    Also known as: ISIS 678354, AKCEA-APOCIII-LRx

  • DrugPlacebo

    SC injection.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Fasting TG at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the jump to reference (J2R) approach.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Percent Change From Baseline in Fasting TG at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  2. Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 Millimoles Per Liter [mmol/L]) at Month 6 With Baseline TG <500 mg/dL (5.65 mmol/L)

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  3. Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 mmol/L) at Month 12 With Baseline TG <500 mg/dL (5.65 mmol/L)

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  4. Percent Change From Baseline in Fasting Apolipoprotein C-III (ApoC-III) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  5. Percent Change From Baseline in Fasting ApoC-III at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  6. Percent Change From Baseline in Fasting Very Low-density Lipoprotein Cholesterol (VLDL-C) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  7. Percent Change From Baseline in VLDL-C at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  8. Percent Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  9. Percent Change From Baseline in Fasting Non-HDL-C at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  10. Percent Change From Baseline in Fasting High-density Lipoprotein Cholesterol (HDL-C) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  11. Percent Change From Baseline in Fasting HDL-C at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  12. Percent Change From Baseline Fasting Remnant Cholesterol (Remnant-C) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  13. Percent Change From Baseline in Fasting Remnant-C at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  14. Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  15. Percent Change From Baseline in Fasting ApoB at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  16. Percent Change From Baseline in Fasting Apolipoprotein A-1 (ApoA-1) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  17. Percent Change From Baseline in Fasting ApoA-1 at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  18. Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  19. Percent Change From Baseline in Fasting LDL-C at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  20. Percent Change From Baseline in Fasting Total Cholesterol (Total-C) at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  21. Percent Change From Baseline in Fasting Total-C at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  22. Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 6

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 6

  23. Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 12

    Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

    Time frame: Baseline, Month 12

  24. Number of Participants With Adjudicated Acute Pancreatitis Events

    All adverse events (AEs) and serious adverse events (SAEs) that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the Acute Pancreatitis Adjudication Committee (PAC) Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. Number of participants with adjudicated acute pancreatitis events were reported.

    Time frame: Up to 12 months

  25. Number of Participants With Adjudicated Acute Pancreatitis Events (≥2 Events in 5 Years Prior to Enrollment)

    The adjudicated acute pancreatitis event rates were compared between pooled olezarsen treatment and placebo group using a negative binomial regression model or Poisson regression model with the treatment group and natural log transformed baseline fasting TG as the factors, and number of adjudicated acute pancreatitis events in 5 years prior to enrollment as a covariate. The logarithm of time in year that each participant observed during the treatment period were used as an offset variable. Number of participants with adjudicated acute pancreatitis events with ≥2 events in 5 years prior to enrollment were reported.

    Time frame: Up to 12 months

07

Results

Posted Apr 23, 2026

Participant flow

Participants took part at 28 clinical sites including 21 sites in the United States (US) and 7 sites in Canada from 01 June 2022 to 17 January 2023.

Participant flow — Overall Study
MilestonePlaceboOlezarsen 50 mgOlezarsen 80 mg
Started395857
Completed385152
Not completed175

Outcome measures

PrimaryPercent Change From Baseline in Fasting TG at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the jump to reference (J2R) approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Fasting TG at Month 6
Percent ChangePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting TG at Month 6-7.77 (-15.34 to -0.21)-57.05 (-63.19 to -50.92)-60.92 (-67.11 to -54.73)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (Analysis of covariance (ANCOVA) included percent change from baseline to Month 6 in fasting TG as the dependent variable, treatment group as a fixed effect, and log-transformed baseline TG value as a covariate.) · Least squares (ls) mean difference: -49.28 · 95% CI -59.02 to -39.54Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting TG as the dependent variable, treatment group as a fixed effect, and log-transformed baseline TG value as a covariate.) · Ls mean difference: -53.15 · 95% CI -62.92 to -43.38Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting TG at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting TG at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting TG at Month 12-5.59 (-13.09 to 1.90)-51.67 (-57.74 to -45.60)-60.39 (-66.51 to -54.27)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting TG as the dependent variable, treatment group as a fixed effect, and log-transformed baseline TG value as a covariate.) · Ls mean difference: -46.07 · 95% CI -55.71 to -36.43Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting TG as the dependent variable, treatment group as a fixed effect, and log-transformed baseline TG value as a covariate.) · Ls mean difference: -54.80 · 95% CI -64.46 to -45.13Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 Millimoles Per Liter [mmol/L]) at Month 6 With Baseline TG <500 mg/dL (5.65 mmol/L)

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 Millimoles Per Liter [mmol/L]) at Month 6 With Baseline TG <500 mg/dL (5.65 mmol/L)
percentage of participantsPlaceboOlezarsen 50 mgOlezarsen 80 mg
Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 Millimoles Per Liter [mmol/L]) at Month 6 With Baseline TG <500 mg/dL (5.65 mmol/L)11.479.284.0
Statistical analysis
  • Placebo vs Olezarsen 50 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 37.51 · 95% CI 10.14 to 138.81The logistic regression model consisted of the treatment group as a factor and log-transformed baseline TG as a covariate.
  • Placebo vs Olezarsen 80 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 62.59 · 95% CI 15.48 to 253.07The logistic regression model consisted of the treatment group as a factor and log-transformed baseline TG as a covariate.
SecondaryPercentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 mmol/L) at Month 12 With Baseline TG <500 mg/dL (5.65 mmol/L)

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 mmol/L) at Month 12 With Baseline TG <500 mg/dL (5.65 mmol/L)
percentage of participantsPlaceboOlezarsen 50 mgOlezarsen 80 mg
Percentage of Participants Who Achieved Fasting TG <150 mg/dL (1.69 mmol/L) at Month 12 With Baseline TG <500 mg/dL (5.65 mmol/L)5.769.882.0
Statistical analysis
  • Placebo vs Olezarsen 50 mg · Regression, Logistic · p = <0.0001 · Odds ratio, log: 38.46 · 95% CI 8.13 to 181.95The logistic regression model consisted of the treatment group as a factor and log-transformed baseline triglycerides as a covariate.
  • Placebo vs Olezarsen 80 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 80.89 · 95% CI 15.95 to 410.36The logistic regression model consisted of the treatment group as a factor and log-transformed baseline triglycerides as a covariate.
SecondaryPercent Change From Baseline in Fasting Apolipoprotein C-III (ApoC-III) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Apolipoprotein C-III (ApoC-III) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Apolipoprotein C-III (ApoC-III) at Month 6-5.47 (-16.46 to 5.51)-69.63 (-79.56 to -59.71)-78.72 (-87.79 to -69.65)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting ApoC-III as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline ApoC-III value as covariate.) · Ls mean difference: -64.16 · 95% CI -74.69 to -53.63Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting ApoC-III as the dependent variable, treatment group, and baseline stratification factor as a fixed effect, log-transformed baseline ApoC-III value as a covariate.) · Ls mean difference: -73.25 · 95% CI -83.94 to -62.55Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting ApoC-III at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting ApoC-III at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting ApoC-III at Month 12-12.40 (-24.02 to -0.77)-69.09 (-79.42 to -58.76)-83.78 (-93.22 to -74.34)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting ApoC-III as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline ApoC-III value as a covariate.) · Ls mean difference: -56.70 · 95% CI -67.73 to -45.66Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting ApoC-III as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline ApoC-III value as a covariate.) · Ls mean difference: -71.39 · 95% CI -82.62 to -60.15Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Very Low-density Lipoprotein Cholesterol (VLDL-C) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Very Low-density Lipoprotein Cholesterol (VLDL-C) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Very Low-density Lipoprotein Cholesterol (VLDL-C) at Month 6-9.74 (-20.65 to 1.17)-55.93 (-65.65 to -46.22)-59.46 (-68.79 to -50.13)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting VLDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline VLDL-C value as covariate.) · Ls mean difference: -46.19 · 95% CI -56.69 to -35.69Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting VLDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline VLDL-C value as covariate.) · Ls mean difference: -49.72 · 95% CI -60.26 to -39.18Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in VLDL-C at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in VLDL-C at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in VLDL-C at Month 12-14.90 (-23.97 to -5.82)-58.00 (-66.11 to -49.88)-66.67 (-74.47 to -58.87)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting VLDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline VLDL-C value as a covariate.) · Ls mean difference: -43.1 · 95% CI -51.88 to -34.32Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting VLDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline VLDL-C value as a covariate.) · Ls mean difference: -51.77 · 95% CI -60.60 to -42.95Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Month 63.28 (-7.04 to 13.61)-22.11 (-31.33 to -12.89)-19.79 (-28.72 to -10.85)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting Non-HDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline Non-HDL-C value as a covariate.) · Ls mean difference: -25.39 · 95% CI -36.33 to -14.46Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting Non-HDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline Non-HDL-C value as a covariate.) · Ls mean difference: -23.07 · 95% CI -34.02 to -12.11Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Non-HDL-C at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Non-HDL-C at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Non-HDL-C at Month 12-2.55 (-11.91 to 6.81)-20.00 (-28.23 to -11.76)-26.57 (-34.59 to -18.55)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = =0.0006 (ANCOVA included percent change from baseline to Month 12 in fasting Non-HDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline Non-HDL-C value as a covariate.) · Ls mean difference: -17.45 · 95% CI -27.37 to -7.52Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting Non-HDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline Non-HDL-C value as a covariate.) · Ls mean difference: -24.02 · 95% CI -33.98 to -14.06Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting High-density Lipoprotein Cholesterol (HDL-C) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting High-density Lipoprotein Cholesterol (HDL-C) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting High-density Lipoprotein Cholesterol (HDL-C) at Month 68.38 (-3.70 to 20.46)48.02 (37.00 to 59.04)48.01 (37.18 to 58.83)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting HDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline HDL-C value as a covariate.) · Ls mean difference: 39.64 · 95% CI 26.71 to 52.57Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting HDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline HDL-C value as a covariate.) · Ls mean difference: 39.63 · 95% CI 26.61 to 52.65Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting HDL-C at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting HDL-C at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting HDL-C at Month 1210.53 (-1.87 to 22.94)54.20 (42.94 to 65.47)57.43 (46.32 to 68.53)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting HDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline HDL-C value as a covariate.) · Ls mean difference: 43.67 · 95% CI 30.39 to 56.95Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting HDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline HDL-C value as a covariate.) · Ls mean difference: 46.89 · 95% CI 33.52 to 60.27Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline Fasting Remnant Cholesterol (Remnant-C) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline Fasting Remnant Cholesterol (Remnant-C) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline Fasting Remnant Cholesterol (Remnant-C) at Month 6-9.46 (-20.39 to 1.47)-55.98 (-65.73 to -46.23)-59.59 (-68.96 to -50.22)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting remnant-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline remnant-C value as a covariate.) · Ls mean difference: -46.52 · 95% CI -57.06 to -35.99Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting remnant-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline remnant-C value as a covariate.) · Ls mean difference: -50.13 · 95% CI -60.71 to -39.56Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Remnant-C at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Remnant-C at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Remnant-C at Month 12-14.83 (-23.85 to -5.82)-58.17 (-66.20 to -50.13)-66.90 (-74.63 to -59.17)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting remnant-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline remnant-C value as a covariate.) · Ls mean difference: -43.33 · 95% CI -52.04 to -34.62Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting remnant-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, log-transformed baseline remnant-C value as a covariate.) · Ls mean difference: -52.07 · 95% CI -60.82 to -43.31Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Month 66.82 (-1.44 to 15.07)-11.42 (-18.80 to -4.03)-11.67 (-18.80 to -4.53)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting ApoB as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline ApoB value as a covariate.) · Ls mean difference: -18.24 · 95% CI -27.11 to -9.36Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting ApoB as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline ApoB value as a covariate.) · Ls mean difference: -18.48 · 95% CI -27.36 to -9.61Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting ApoB at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting ApoB at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting ApoB at Month 120.68 (-7.09 to 8.44)-11.67 (-18.45 to -4.90)-18.53 (-25.12 to -11.93)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = =0.0038 (ANCOVA included percent change from baseline to Month 12 in fasting ApoB as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline ApoB value as a covariate.) · Ls mean difference: -12.35 · 95% CI -20.70 to -3.99Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting ApoB as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline ApoB value as a covariate.) · Ls mean difference: -19.2 · 95% CI -27.58 to -10.82Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Apolipoprotein A-1 (ApoA-1) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Apolipoprotein A-1 (ApoA-1) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Apolipoprotein A-1 (ApoA-1) at Month 62.84 (-2.19 to 7.87)17.37 (12.82 to 21.93)14.91 (10.49 to 19.32)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting ApoA-1 as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline ApoA-1 value as a covariate.) · Ls mean difference: 14.53 · 95% CI 9.11 to 19.96Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 6 in fasting ApoA-1 as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline ApoA-1 value as a covariate.) · Ls mean difference: 12.07 · 95% CI 6.62 to 17.52Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting ApoA-1 at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting ApoA-1 at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting ApoA-1 at Month 120.81 (-4.11 to 5.72)16.37 (11.97 to 20.78)15.46 (11.15 to 19.76)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting ApoA-1 as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline ApoA-1 value as a covariate.) · Ls mean difference: 15.57 · 95% CI 10.26 to 20.87Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = <0.0001 (ANCOVA included percent change from baseline to Month 12 in fasting ApoA-1 as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline ApoA-1 value as a covariate.) · Ls mean difference: 14.65 · 95% CI 9.32 to 19.99Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Month 640.46 (25.11 to 55.80)30.61 (16.44 to 44.77)32.74 (19.35 to 46.14)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = =0.2413 (ANCOVA included percent change from baseline to Month 6 in fasting LDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline LDL-C value as a covariate.) · Ls mean difference: -9.85 · 95% CI -26.33 to 6.63Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = =0.3579 (ANCOVA included percent change from baseline to Month 6 in fasting LDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline LDL-C value as a covariate.) · Ls mean difference: -7.71 · 95% CI -24.16 to 8.73Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting LDL-C at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting LDL-C at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting LDL-C at Month 1235.08 (21.09 to 49.08)32.99 (20.52 to 45.46)27.27 (15.28 to 39.26)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = =0.7850 (ANCOVA included percent change from baseline to Month 12 in fasting LDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline LDL-C value as a covariate.) · Ls mean difference: -2.09 · 95% CI -17.15 to 12.96Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = =0.3099 (ANCOVA included percent change from baseline to Month 12 in fasting LDL-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline LDL-C value as a covariate.) · Ls mean difference: -7.81 · 95% CI -22.90 to 7.27Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Total Cholesterol (Total-C) at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Total Cholesterol (Total-C) at Month 6
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Total Cholesterol (Total-C) at Month 62.99 (-4.94 to 10.92)-6.78 (-13.86 to 0.30)-6.48 (-13.31 to 0.35)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = =0.0238 (ANCOVA included percent change from baseline to Month 6 in fasting total-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline total-C value as a covariate.) · Ls mean difference: -9.77 · 95% CI -18.25 to -1.30Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = =0.0289 (ANCOVA included percent change from baseline to Month 6 in fasting total-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline total-C value as a covariate.) · Ls mean difference: -9.47 · 95% CI -17.97 to -0.97Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercent Change From Baseline in Fasting Total-C at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Total-C at Month 12
percent changePlaceboOlezarsen 50 mgOlezarsen 80 mg
Percent Change From Baseline in Fasting Total-C at Month 12-2.15 (-9.25 to 4.95)-6.08 (-12.35 to 0.18)-10.80 (-16.87 to -4.72)
Statistical analysis
  • Placebo vs Olezarsen 50 mg · ANCOVA · p = =0.3107 (ANCOVA included percent change from baseline to Month 12 in fasting total-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline total-C value as a covariate.) · Ls mean difference: -3.93 · 95% CI -11.53 to 3.67Difference in the LS mean was calculated as olezarsen 50 mg - placebo.
  • Placebo vs Olezarsen 80 mg · ANCOVA · p = =0.0264 (ANCOVA included percent change from baseline to Month 12 in fasting total-C as the dependent variable, treatment group, baseline stratification factor as a fixed effect, and log-transformed baseline total-C value as a covariate.) · Ls mean difference: -8.65 · 95% CI -16.27 to -1.02Difference in the LS mean was calculated as olezarsen 80 mg - placebo.
SecondaryPercentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 6

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 6 was defined as the average of Weeks 25 and 27. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 6
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 6
percentage of participantsPlaceboOlezarsen 50 mgOlezarsen 80 mg
Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 675.080.0100.0
Statistical analysis
  • Placebo vs Olezarsen 50 mg · Regression, Logistic · p = =0.4212 · Odds ratio (or): 4.46 · 95% CI 0.12 to 169.94The logistic regression model consisted of the treatment group as a factor and log-transformed baseline TG as a covariate.
  • Placebo vs Olezarsen 80 mg · Regression, Logistic · p = =0.3281 · Odds ratio (or): 5.74 · 95% CI 0.17 to 190.69The logistic regression model consisted of the treatment group as a factor and log-transformed baseline TG as a covariate.
SecondaryPercentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 12

Baseline was defined as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If the Day 1 pre-dose and qualification period measurements were all missing, then the last non-missing measurement from the screening period was used as baseline. Month 12 was defined as the average of Weeks 51 and 53. If 1 of the 2 assessments was missing, then the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using the J2R approach.

Time frame:
Baseline, Month 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 12
percentage of participantsPlaceboOlezarsen 50 mgOlezarsen 80 mg
Percentage of Participants Who Achieved Fasting TG <500 mg/dL (5.65 mmol/L) With Baseline TG ≥500 mg/dL at Month 1275.0100.0100.0
Statistical analysis
  • Placebo vs Olezarsen 50 mg · Regression, Logistic · p = =0.4722 · Odds ratio (or): 4.49 · 95% CI 0.07 to 270.10The logistic regression model consisted of the treatment group as a factor and log-transformed baseline TG as a covariate.
  • Placebo vs Olezarsen 80 mg · Regression, Logistic · p = =0.3271 · Odds ratio (or): 7.3 · 95% CI 0.14 to 388.49The logistic regression model consisted of the treatment group as a factor and log-transformed baseline TG as a covariate.
SecondaryNumber of Participants With Adjudicated Acute Pancreatitis Events

All adverse events (AEs) and serious adverse events (SAEs) that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the Acute Pancreatitis Adjudication Committee (PAC) Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. Number of participants with adjudicated acute pancreatitis events were reported.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Adjudicated Acute Pancreatitis Events
ParticipantsPlaceboOlezarsen 50 mgOlezarsen 80 mg
Number of Participants With Adjudicated Acute Pancreatitis Events000
SecondaryNumber of Participants With Adjudicated Acute Pancreatitis Events (≥2 Events in 5 Years Prior to Enrollment)

The adjudicated acute pancreatitis event rates were compared between pooled olezarsen treatment and placebo group using a negative binomial regression model or Poisson regression model with the treatment group and natural log transformed baseline fasting TG as the factors, and number of adjudicated acute pancreatitis events in 5 years prior to enrollment as a covariate. The logarithm of time in year that each participant observed during the treatment period were used as an offset variable. Number of participants with adjudicated acute pancreatitis events with ≥2 events in 5 years prior to enrollment were reported.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Adjudicated Acute Pancreatitis Events (≥2 Events in 5 Years Prior to Enrollment)
ParticipantsPlaceboOlezarsen 50 mgOlezarsen 80 mg
Number of Participants With Adjudicated Acute Pancreatitis Events (≥2 Events in 5 Years Prior to Enrollment)000

Adverse events

Collected over Up to 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/39 (0%)2/39 (5.1%)22/39 (56.4%)
Olezarsen 50 mg1/58 (1.7%)6/58 (10.3%)32/58 (55.2%)
Olezarsen 80 mg0/57 (0%)8/57 (14%)24/57 (42.1%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPlaceboOlezarsen 50 mgOlezarsen 80 mg
Tibia fractureInjury, poisoning and procedural complications1/390/581/57
Head injuryInjury, poisoning and procedural complications1/390/580/57
Ligament sprainInjury, poisoning and procedural complications1/390/580/57
Endometrial cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/390/580/57
SyncopeNervous system disorders1/390/580/57
Angina pectorisCardiac disorders0/390/581/57
TachycardiaCardiac disorders0/390/581/57
Small intestinal obstructionGastrointestinal disorders0/390/581/57
Drug withdrawal syndromeGeneral disorders0/390/581/57
SepsisInfections and infestations0/391/581/57
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlaceboOlezarsen 50 mgOlezarsen 80 mg
Urinary tract infectionInfections and infestations6/396/583/57
Injection site erythemaGeneral disorders0/398/582/57
FatigueGeneral disorders1/396/581/57
SinusitisInfections and infestations4/391/581/57
COVID-19Infections and infestations2/395/584/57
Back painMusculoskeletal and connective tissue disorders1/395/581/57
ArthralgiaMusculoskeletal and connective tissue disorders2/395/580/57
BronchitisInfections and infestations3/393/580/57
Glomerular filtration rate decreasedInvestigations3/391/580/57
Diabetes mellitusMetabolism and nutrition disorders1/394/584/57

Baseline characteristics

Full analysis set (FAS) included all participants who were randomized and received any amount of study drug (olezarsen or placebo) and who have at least one post-baseline TG assessment.

Age, Continuous
Age, Continuous(years)PlaceboOlezarsen 50 mgOlezarsen 80 mgTotal
Mean63.3 ± 9.5262.3 ± 10.1560.4 ± 10.7761.8 ± 10.24
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOlezarsen 50 mgOlezarsen 80 mgTotal
Female24241765
Male15344089
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOlezarsen 50 mgOlezarsen 80 mgTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American53513
White345452140
More than one race0000
Unknown or Not Reported0000
Fasting Triglycerides (TG)
Fasting Triglycerides (TG)(milligrams/deciliter (mg/dL))PlaceboOlezarsen 50 mgOlezarsen 80 mgTotal
Mean302.1 ± 201.91292.1 ± 183.01315.1 ± 221.63303.2 ± 201.7
08

Study locations

24 sites
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Excel Medical Clinical Trials, LLC
    Boca Raton, Florida 33434, United States
  • De La Cruz Research Center
    Miami, Florida 33184, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Research Physicians Network Alliance
    Winter Park, Florida 32792, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • Evanston Premier Healthcare Research
    Evanston, Illinois 60201, United States
  • Clinical Investigation Specialist
    Gurnee, Illinois 60031, United States
  • West Broadway Clinic
    Council Bluffs, Iowa 51501, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
    Louisville, Kentucky 40213, United States
  • Aa Mrc, Llc
    Flint, Michigan 48504, United States
  • Clinical Research of South Nevada
    Las Vegas, Nevada 89121, United States
  • Palm Research Center, Inc.
    Las Vegas, Nevada 89148, United States
  • Green and Seidner Family Practice Associates
    Lansdale, Pennsylvania 19446, United States
  • Main Street Physicians Care Waterway
    Little River, South Carolina 29566, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Tennessee Center for Clinical Trials
    Tullahoma, Tennessee 37388, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • York Clinical Research LLC
    Norfolk, Virginia 23504, United States
  • Bluewater Clinical Research Group Inc
    Sarnia, Ontario N7t 4X3, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Clinique des Maladies Lipidiques de Quebec Inc.
    Québec, G1V 4W2, Canada
09

References and documents

Publications

  • Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Murphy SA, Goodrich EL, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS; Bridge-TIMI 73a Investigators. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 2024 May 16;390(19):1770-1780. doi: 10.1056/NEJMoa2402309. Epub 2024 Apr 7. PubMed 38587249 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Mar 2023, 10 months.

Results were first posted in Apr 2026, 3 years 1 month after primary completion. A results delay was requested in Feb 2024.

Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 2, 2022
StartActual
May 9, 2022
Primary completionActual
Mar 22, 2023
CompletionActual
Dec 21, 2023
Results delay requested
Feb 26, 2024
Results first posted
Apr 23, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05355402
Responsible party
Sponsor
First posted
May 2, 2022
Start date
May 9, 2022
Primary completion
Mar 22, 2023
Completion
Dec 21, 2023
Results posted
Apr 23, 2026
Last update
Apr 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olezarsen

Start the discussion